文献速递糖尿病

COVID-19后新发糖尿病

New-Onset Diabetes After COVID-19.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

本文是一篇小型综述,检索PubMed、MEDLINE和medRxiv至2022年12月1日,探讨COVID-19后新发糖尿病(NODAC)的证据。现有证据提示COVID-19增加糖尿病风险,但因研究设计局限及疫情演变,归因风险不确定;病因可能为多因素,作者建议将糖尿病列为COVID后综合征。

要点

  • COVID-19后新发糖尿病(NODAC)证据提示感染增加糖尿病风险,但归因风险不确定。
  • 病因可能涉及宿主特征、社会健康决定因素及疫情相关个人与社会层面影响。
  • 作者建议将糖尿病视为COVID后综合征,以便研究其病理生理、自然史和最佳管理。

核心结论

  • 现有证据提示COVID-19增加糖尿病风险,但归因风险因研究设计局限和疫情演变而不确定。
  • 作者认为应考虑将糖尿病列为COVID后综合征,以便研究其病理生理、自然史和最佳管理。

研究设计与样本

  • 小型综述,检索PubMed、MEDLINE和medRxiv自建库至2022年12月1日,使用医学主题词(MeSH)和自由词,并补充检索参考文献列表。

主要发现

  • COVID-19后糖尿病的病因可能为多因素,包括宿主特征(如年龄)、社会健康决定因素(如剥夺指数)以及疫情相关的个人(如心理社会压力)和社会社区层面(如隔离措施)影响。
  • COVID-19可能通过急性感染及其治疗(如糖皮质激素)、自身免疫、病毒在多器官包括脂肪组织中的持续存在、内皮功能障碍和高炎症状态,对胰腺β细胞功能和胰岛素敏感性产生直接和间接影响。

临床怎么用

  • 作者认为应考虑将糖尿病列为COVID后综合征,而非仅按传统分类(如1型或2型糖尿病)。

局限性

  • 归因风险因研究设计局限和疫情演变(包括新变异株、广泛人群暴露、COVID-19诊断选项和疫苗接种状态)而不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is evidence suggesting that infection with SARS-CoV-2 can lead to several long-term sequelae including diabetes. This mini-review examines the rapidly evolving and conflicting literature on new-onset diabetes after COVID-19, which we term NODAC. We searched PubMed, MEDLINE, and medRxiv from inception until December 1, 2022, using Medical Subject Headings (MeSH) terms and free text words including "COVID-19," "SARS-CoV-2," "diabetes," "hyperglycemia," "insulin resistance," and "pancreatic β-cell." We also supplemented searches by examining reference lists from retrieved articles. Current evidence suggests that COVID-19 increases the risk of developing diabetes, but the attributable risk is uncertain because of limitations of study designs and the evolving nature of the pandemic, including new variants, widespread population exposure to the virus, diagnostic options for COVID-19, and vaccination status. The etiology of diabetes after COVID-19 is likely multifactorial and includes factors associated with host characteristics (eg, age), social determinants of health (eg, deprivation index), and pandemic-related effects both at the personal (eg, psychosocial stress) and the societal-community level (eg, containment measures). COVID-19 may have direct and indirect effects on pancreatic β-cell function and insulin sensitivity related to the acute infection and its treatment (eg, glucocorticoids); autoimmunity; persistent viral residency in multiple organs including adipose tissue; endothelial dysfunction; and hyperinflammatory state. While our understanding of NODAC continues to evolve, consideration should be given for diabetes to be classified as a post-COVID syndrome, in addition to traditional classifications of diabetes (eg, type 1 or type 2), so that the pathophysiology, natural history, and optimal management can be studied.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kim SH, Arora I, Hsia DS, et al. New-Onset Diabetes After COVID-19. J Clin Endocrinol Metab. 2023. PMID: 37207448. doi:10.1210/clinem/dgad284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。